Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LataMed AILMEDD +9.76%26 3-Year RORE % is -43.50 as of Mar. 2026. GuruFocus rates LMEDD with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 2,543 Software companies, LataMed AI ranks worse than 77.39% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
LataMed AI's 3-Year RORE % for the quarter that ended in Mar. 2026 was -43.50%.
The industry rank for LataMed AI's 3-Year RORE % or its related term are showing as below:
LMEDD's 3-Year RORE % is ranked worse than 77.39% of 2543
companies
in the Software industry
Industry Median: 3.07
vs LMEDD: -43.50
LataMed AI (OTCPK:LMEDD) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
LataMed AI 3-Year RORE % Related Terms
LataMed AI 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for LataMed AI's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LMEDD vs KLTR, BZAI, THRY: 3-Year RORE % Comparison
For the Software - Application subindustry, LataMed AI's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LataMed AI 3-Year RORE % vs Software Industry
For the Software industry and Technology sector, LataMed AI's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where LataMed AI's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
LataMed AI (LMEDD) has a 3-Year RORE % of -43.50 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on LataMed AI and its competitors. According to the industry distribution chart, LataMed AI ranks #1968 out of 2543 companies in the Software industry, placing it in the top 77.4%.
Is LataMed AI's 3-Year RORE % too high?
LataMed AI's current 3-Year RORE % is -43.50. Based on the distribution chart, LataMed AI ranks #1968 out of 2543 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, LataMed AI has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does LataMed AI's 3-Year RORE % compare to KLTR and BZAI?
According to the Software industry distribution chart, LataMed AI ranks #1968 out of 2543 companies for 3-Year RORE %. This places LataMed AI in the lower half of its industry. The industry median 3-Year RORE % is 3.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Software company?
The median 3-Year RORE % among Software companies is 3.07, based on 2,543 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on LataMed AI and its competitors. For the Software industry, the median 3-Year RORE % is 3.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LataMed AI's current 3-Year RORE % is -43.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LataMed AI stock overvalued right now?
LataMed AI (LMEDD) has a current 3-Year RORE % of -43.50. The current 3-Year RORE % is -43.50. LataMed AI's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For LataMed AI (LMEDD), the current 3-Year RORE % is -43.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LataMed AI Corp is a technology company focused on the development and deployment of artificial intelligence-driven healthcare solutions across Latin America. Its healthcare platform includes AI-enabled analytics, telehealth infrastructure, and coordinated care systems designed to support healthcare delivery in emerging markets. The company develops digital infrastructure for patient prioritization, clinical workflow management, telehealth access, care coordination, and healthcare system operations. It holds issued patents for its core AI modules-CardioAI, PulmoAI, and NeuroAI-which deliver predictive analytics for cardiovascular, pulmonary, and neurological disease detection and management.
26GF Score
Get the complete analysis for LMEDD
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMEDD has been successfully added to your 
